Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 12/20 | 0.63 |
| ▸ | STS | P08842 | 11/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16879886 | 0.88 | CYP19A1 (0.60) | CYP19A1STSCA2 | |
| SCHEMBL16879973 | 0.88 | CYP19A1 (0.60) | CYP19A1STSCA2AGTR2GRM2 | |
| SCHEMBL16879639 | 0.86 | CSF1R (0.59) | CYP19A1STSCYP11B1CYP11B2LMNA | |
| SCHEMBL16879836 | 0.86 | CYP19A1 (0.50) | CYP19A1STSCA2CYP11B1CYP11B2 | |
| SCHEMBL16879690 | 0.86 | STS (0.48) | CYP19A1STSCYP11B1CYP11B2LMNA | |
| SCHEMBL16879845 | 0.83 | CYP19A1 (0.60) | CYP19A1STSCA2GRM2 | |
| SCHEMBL16879754 | 0.81 | CYP11B1 (0.51) | CYP19A1CYP11B1CYP11B2LMNAHTT | |
| SCHEMBL16879469 | 0.81 | CYP19A1 (0.58) | CYP19A1STSCA2AGTR2GRM2 | |
| SCHEMBL16879687 | 0.81 | CYP19A1 (0.43) | CYP19A1STSCYP11B1CYP11B2LMNA | |
| SCHEMBL16879648 | 0.80 | CYP19A1 (0.41) | CYP19A1STSCYP11B1CYP11B2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3089966-B1 | NEW SUBSTITUTED BIPHENYL ANALOGUES AS DUAL INHIBITORS OF AROMATASE AND SULFATASE | ESTRYX PHARMA LTD (GB) | 2020-10-21 | — | — | EP | disclosed |
| US-9682941-B2 | Substituted biphenyl analogues as dual inhibitors of aromatase and sulfatase | ESTRYX PHARMA LIMITED (GB) | 2017-06-20 | — | — | US | disclosed |
| US-20170001964-A1 | NEW SUBSTITUTED BIPHENYL ANALOGUES AS DUAL INHIBITORS OF AROMATASE AND SULFATASE | BEAUFOUR IPSEN TIANJIN PHARMACEUTICAL CO., LTD (CN) | 2017-01-05 | — | — | US | disclosed |
| EP-3089966-A1 | NEW SUBSTITUTED BIPHENYL ANALOGUES AS DUAL INHIBITORS OF AROMATASE AND SULFATASE | Beaufour Ipsen Tianjin Pharmaceutical Co., Ltd (CN) | 2016-11-09 | — | — | EP | disclosed |
| WO-2015100609-A1 | NEW SUBSTITUTED BIPHENYL ANALOGUES AS DUAL INHIBITORS OF AROMATASE AND SULFATASE | BEAUFOUR IPSEN TIANJIN PHARMACEUTICAL CO., LTD (CN) | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001964-A1 | NEW SUBSTITUTED BIPHENYL ANALOGUES AS DUAL INHIBITORS OF AROMATASE AND SULFATASE | CYP19A1, SULT2A1, STS | CYP19A1 1/4885STS 3/4885CA2 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.